Jun 2026 (Q2 FY26) — Aug 10, 2026
Tactile Systems Technology Q2 FY26 — Strong Lymphedema Growth and Profitability Expansion Offset Airway Clearance Headwinds
Read the full callTactile Systems Technology (TCMD) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Tactile Systems Technology earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 85.7 | +8.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 8.0 | +2.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 7.8 | +142.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$22.73 +0.93% · +$0.21
Performance +56.4% 1Y
1Y: $14.53 on 17 Oct 2025 → $22.73. High $33.05 (18 Feb 2026), low $14.53 (17 Oct 2025).
- Previous close
- $22.52
- 52-week range
- $14.61 – $33.05
- One year
- +55.58%
Overview
- Symbol
- TCMD
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Tactile Systems Technology earnings calls (TCMD)
Financials
What the filings say
Net profit, year on year: +142% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 73 | 86 | 61 | 79 | 86 | 104 | 75 | 86 |
| Operating profit | 7 | 13 | -5 | 4 | 11 | 19 | -2 | 7 |
| Operating margin | 9.3% | 14.6% | −7.4% | 5.2% | 12.8% | 18.1% | −2.0% | 8.0% |
| Other income | 0 | — | — | — | — | — | — | — |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 7 | 13 | -4 | 5 | 11 | 19 | -1 | 7 |
| Tax rate | 28.7% | 25.2% | 26.9% | 28.9% | 28.2% | 45.3% | −96.8% | −5.7% |
| Net profit | 5 | 10 | -3 | 3 | 8 | 11 | -2 | 8 |
| EPS ($ per share) | 0.21 | — | -0.13 | 0.14 | 0.37 | — | -0.08 | 0.34 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 10 | 21 | 20 | 8 | -10 | 19 | 36 | 55 |
| Total liabilities | 18 | 39 | 49 | 116 | 134 | 88 | 81 | 55 |
| Fixed assets | 5 | 7 | 7 | 7 | 6 | 6 | 6 | 5 |
| Total assets | 107 | 152 | 174 | 244 | 255 | 281 | 298 | 274 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 9 | 3 | 3 | 3 | 5 | 36 | 41 | 43 |
| Cash from investing | -15 | -2 | 20 | -82 | -2 | -2 | -2 | -3 |
| Cash from financing | 2 | 2 | 2 | 60 | -10 | 6 | -5 | -51 |
| Capital expenditure | -4 | -5 | -2 | -2 | -2 | -2 | -2 | -2 |
| Free cash flow | 5 | -3 | 1 | 1 | 3 | 34 | 38 | 40 |
Insider filings
32 filings between Jan 2, 2026 and Aug 10, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.02M
12 sales by 3 insiders
8% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 20
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Dodd Sheri Louise | — | $1.07M | Aug 10, 2026 |
| Birkemeyer Elaine M. | — | $492.4K | May 11, 2026 |
| Burns Kristie | — | $454.6K | Feb 24, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 10, 2026 | Dodd Sheri Louise Chief Executive Officer | Sale | 10,978 | $323.2K |
| May 11, 2026 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Sale | 4,631 | $113.4K |
| May 6, 2026 | Volkart Carmen B Director | Award | 6,521 | $0 |
| May 6, 2026 | Pearson Andrea Director | Award | 6,521 | $0 |
| May 6, 2026 | Huggenberger Raymond Director | Award | 6,521 | $0 |
| May 6, 2026 | Shafer David Brent Director | Award | 6,521 | $0 |
| May 6, 2026 | Washington Boyd Vindell Director | Award | 6,521 | $0 |
| May 6, 2026 | King Laura G. Director | Award | 6,521 | $0 |
| May 6, 2026 | Asbury Valerie L. Director | Award | 6,521 | $0 |
| May 6, 2026 | BURKE WILLIAM W Director | Award | 6,521 | $0 |
| Mar 9, 2026 | Pearson Andrea Director | Award | 852 | $0 |
| Feb 24, 2026 | Dodd Sheri Louise Chief Executive Officer | Sale | 10,993 | $318.1K |
| Feb 24, 2026 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale | 6,246 | $180.8K |
| Feb 24, 2026 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Sale | 7,701 | $222.9K |
| Feb 23, 2026 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Sale | 196 | $5.6K |
| Feb 23, 2026 | Dodd Sheri Louise Chief Executive Officer | Sale | 14,703 | $415.8K |
| Feb 23, 2026 | Dodd Sheri Louise Chief Executive Officer | Sale | 537 | $15.4K |
| Feb 23, 2026 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale | 4,279 | $121.0K |
| Feb 23, 2026 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale | 160 | $4.6K |
| Feb 23, 2026 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Sale | 5,322 | $150.5K |
| Feb 20, 2026 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Award | 7,123 | $0 |
| Feb 20, 2026 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Award | 15,575 | $0 |
| Feb 20, 2026 | Dodd Sheri Louise Chief Executive Officer | Award | 19,751 | $0 |
| Feb 20, 2026 | Dodd Sheri Louise Chief Executive Officer | Award | 28,216 | $0 |
| Feb 20, 2026 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Award | 3,579 | $0 |
| Feb 20, 2026 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Award | 6,765 | $0 |
| Feb 20, 2026 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Award | 3,490 | $0 |
| Feb 20, 2026 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Award | 4,058 | $0 |
| Feb 19, 2026 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Award | 23,008 | $0 |
| Feb 19, 2026 | Dodd Sheri Louise Chief Executive Officer | Award | 48,672 | $0 |
| Feb 19, 2026 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Award 10b5-1 plan | 6,194 | $0 |
| Jan 2, 2026 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale 10b5-1 plan | 5,139 | $148.3K |
| Aug 8, 2025 | Dodd Sheri Louise Chief Executive Officer | Sale | 7,762 | $95.9K |
| May 12, 2025 | Birkemeyer Elaine M. Chief Financial Officer | Sale 10b5-1 plan | 2,921 | $29.0K |
| May 8, 2025 | Dodd Sheri Louise Chief Executive Officer | Sale | 3,149 | $31.0K |
| May 8, 2025 | BURKE WILLIAM W Director | Sale 10b5-1 plan | 3,300 | $31.9K |
| May 7, 2025 | Asbury Valerie L. Director | Award | 16,078 | $0 |
| May 7, 2025 | BURKE WILLIAM W Director | Award 10b5-1 plan | 16,078 | $0 |
| May 7, 2025 | King Laura G. Director | Award | 16,078 | $0 |
| May 7, 2025 | Washington Boyd Vindell Director | Award | 16,078 | $0 |
| May 7, 2025 | Volkart Carmen B Director | Award | 16,078 | $0 |
| May 7, 2025 | Shafer David Brent Director | Award | 16,078 | $0 |
| May 7, 2025 | Huggenberger Raymond Director | Award | 16,078 | $0 |
| Mar 11, 2025 | REUVERS DANIEL L. Director | Gift | 68,162 | $0 |
| Mar 11, 2025 | REUVERS DANIEL L. Director | Gift | 68,162 | $0 |
| Feb 25, 2025 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale | 6,468 | $93.2K |
| Feb 25, 2025 | REUVERS DANIEL L. Director | Sale 10b5-1 plan | 28,338 | $401.8K |
| Feb 25, 2025 | Birkemeyer Elaine M. Chief Financial Officer | Sale 10b5-1 plan | 2,066 | $30.0K |
| Feb 24, 2025 | REUVERS DANIEL L. Director | Sale 10b5-1 plan | 10,938 | $159.1K |
| Feb 24, 2025 | Birkemeyer Elaine M. Chief Financial Officer | Sale 10b5-1 plan | 3,778 | $55.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for TACTILE SYSTEMS TECHNOLOGY INC
Free account. Everything above stays public.
Write why you follow TACTILE SYSTEMS TECHNOLOGY INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading